David Biggs, MD
Hematology & Oncology · Frisco, CONPI 1578532511
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $491 and has fallen 94.8% since, to $26 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CO, where the typical reported total is $1,826.
Across 55 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$241
- AstraZeneca$210
- Merck$188
- E.r. Squibb & Sons, L.L.C.$145
- Pharmacyclics LLC, An Abbvie Company$140
- Johnson & Johnson$96
- plus $364 from 14 others
What the payments were for
- Food & beverage$1,37199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 1 | $241 |
| AstraZeneca(2 entities) | 10 | $210 |
| Merck | 9 | $188 |
| E.r. Squibb & Sons, L.L.C. | 3 | $145 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $140 |
| Johnson & Johnson(2 entities) | 5 | $96 |
| Bristol Myers Squibb | 4 | $88 |
| Genentech USA, Inc. | 3 | $44 |
| Amgen | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Eisai Inc. | 2 | $28 |
| Sanofi | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOPTELET$241
How this compares
$1,383 in reported general payments places this provider in the 45th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 13 | $259,312 |
| JakafiRuxolitinib Phosphate | 12 | $211,198 |
| Deferasirox | 11 | $153,802 |
| EliquisApixaban | 19 | $22,989 |
| Anastrozole | 36 | $893 |
| Dexamethasone | 14 | $172 |
| Ondansetron Hcl | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Frisco
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.